Financial Gravity Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Financial Gravity Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-104	Closed	-$31K	–	1001
2021 Q2	$31K	Buy	+104	New	+$3.19K	0.01%	706
2019 Q4	–	Sell	-16	Closed	–	–	1680
2019 Q3	$0	Buy	16 +4	+33%	+$119	﹤0.01%	1530
2019 Q2	$0	Sell	12 -1,209	-99%	-$41.4K	﹤0.01%	1639
2019 Q1	$44K	Buy	+1,221	New	+$45.4K	0.04%	343
2018 Q3	$2K	Sell	47 -11	-19%	-$543	﹤0.01%	1004
2018 Q2	$3K	Buy	58 +30	+107%	+$1.55K	﹤0.01%	912
2018 Q1	$1K	Buy	+28	New	+$1.17K	﹤0.01%	1260

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return

Financial Gravity Asset Management's SUPN Position: Q3 2021 in Review

Financial Gravity Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2021, closing a stake of 104 shares — an estimated $31K sold.

Financial Gravity Asset Management first reported a position in SUPN in Q1 2018 and held it in 7 quarters. The position peaked at $44K in Q1 2019. 223 funds tracked by Wall St. Rank hold SUPN as of Q3 2021.

Financial Gravity Asset Management reported no remaining Supernus Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Financial Gravity Asset Management sold 104 Supernus Pharmaceuticals shares in Q3 2021, an estimated $31K.
Financial Gravity Asset Management first reported a position in Supernus Pharmaceuticals in Q1 2018 and held it in 7 quarters.
Financial Gravity Asset Management's Supernus Pharmaceuticals position peaked at $44K in Q1 2019.
223 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2021.

Based on Financial Gravity Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.